Form 4: Nurix Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 3,847 shares of common stock on July 30, 2026 for $23.38 per share.
Summary
- Option exercise/conversion: acquired 3,750 Common Stock on July 30, 2026; holds 118,755 after (Direct).
- Option exercise/conversion: acquired 2,858 Common Stock on July 30, 2026; holds 121,613 after (Direct).
- Option exercise/conversion: acquired 3,572 Common Stock on July 30, 2026; holds 125,185 after (Direct).
- Open-market sale: disposed of 3,847 Common Stock at $23.38 ($89,954) on July 30, 2026; holds 121,338 after (Direct).
- Option exercise/conversion: disposed of 3,750 Restricted Stock Units on July 30, 2026; holds 11,250 after (Direct).
- Option exercise/conversion: disposed of 2,858 Restricted Stock Units on July 30, 2026; holds 20,009 after (Direct).
- Option exercise/conversion: disposed of 3,572 Restricted Stock Units on July 30, 2026; holds 39,303 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $89,954 of stock on the open market.
Insider Transactions
Gwenn Hansen — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-30 | Option exercise/conversion | Common Stock | 3,750 | — | — | 118,755 |
| 2026-07-30 | Option exercise/conversion | Common Stock | 2,858 | — | — | 121,613 |
| 2026-07-30 | Option exercise/conversion | Common Stock | 3,572 | — | — | 125,185 |
| 2026-07-30 | Open-market sale | Common Stock | 3,847 | $23 | $90.0K | 121,338 |
| 2026-07-30 | Option exercise/conversion | Restricted Stock Units | 3,750 | — | — | 11,250 |
| 2026-07-30 | Option exercise/conversion | Restricted Stock Units | 2,858 | — | — | 20,009 |
| 2026-07-30 | Option exercise/conversion | Restricted Stock Units | 3,572 | — | — | 39,303 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-30 | Option exercise/conversion (3,750 shares) |
| 2026-07-30 | Option exercise/conversion (2,858 shares) |
| 2026-07-30 | Option exercise/conversion (3,572 shares) |
| 2026-07-30 | Open-market sale (3,847 shares) |
| 2026-07-30 | Option exercise/conversion (3,750 shares) |
| 2026-07-30 | Option exercise/conversion (2,858 shares) |
| 2026-07-30 | Option exercise/conversion (3,572 shares) |
Keywords
insider transaction, Form 4, NRIX, Nurix Therapeutics, Inc., bearish, Gwenn Hansen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.